DR. DAVID JOHN WYLER, M.D.
Osteopathic Medicine at North, Newton, MA
License number
Massachusetts 44458
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
2014 North St NORTH, Newton, MA 02462
Phone
(617) 243-6000
(617) 527-6737 (Fax)
(617) 964-3960
(617) 527-6737 (Fax)
(617) 964-3960
Personal information
See more information about DAVID JOHN WYLER at radaris.comName
Address
Phone
128 Vernal St, Everett, MA 02149
194 Ward St, Newton Center, MA 02459
194 Ward St, Newton Center, MA 02459
5 Trotters Ln, Vineyard Haven, MA 02568
5 Trotter, Newton Center, MA 02459
Professional information
See more information about DAVID JOHN WYLER at trustoria.com
David John Wyler, Boston MA
David John Wyler, Boston MA
Specialties:
Internal Medicine, Infectious Disease
Work:
New England Eye Center
750 Washington St, Boston, MA 02111 Newton-Wellesley Hospital
2014 Washington St, Newton Lower Falls, MA 02462
750 Washington St, Boston, MA 02111 Newton-Wellesley Hospital
2014 Washington St, Newton Lower Falls, MA 02462
Education:
Harvard University(1970)
Fibroblast Stimulating Growth Factor 1 (Fsf-1) And The Early Detection Of Fibrosis
Fibroblast Stimulating Growth Factor 1 (Fsf-1) And The Early Detection Of Fibrosis
US Patent:
6214968, Apr 10, 2001
Filed:
Jun 5, 1995
Appl. No.:
8/465343
Inventors:
David J. Wyler - Newton MA
Sadhana Prakash - Cambridge MA
Xiaoping Zhang - Malden MA
Sadhana Prakash - Cambridge MA
Xiaoping Zhang - Malden MA
Assignee:
New England Medical Center Hospitals, Inc. - Boston MA
International Classification:
C07K 1400, C07K 1452
US Classification:
530300
Abstract:
A method for identifying individuals with a propensity for pathological fibrosis. The method involves providing a sample from an individual with a chronic inflammatory disease, contacting the sample with an antibody specific for fibroblast stimulating factor-1 (FsF-1) under conditions which permit immunocomplex formation, and detecting an increase in the relative level of the immunocomplex as an indication of a propensity for pathological fibrosis. FsF-1 polypeptides and antibodies specific for FsF-1, and DNA sequences encoding FsF-1 polypeptides are also disclosed.